Johnson & Johnson's Q1 2013 earnings beat expectations, with strong pharmaceutical sales growth and encouraging developments like the FDA approval of INVOKANA for type 2 diabetes. Despite some challenges in the Medical Devices and Diagnostics segment, the company raised its full-year operational sales and earnings guidance, reflecting confidence in its performance. This positive earnings report and optimistic outlook are likely to have a favorable short-term impact on the stock price.

[1]